BDGR, FMNJ, AMIE, DSCO, SCII, SPDE OTCPicks.com Stocks to Watch for Monday, September 14th

Our Stocks to Watch tomorrow include Black Dragon Resource Companies Inc. (OTC: BDGR), Franklin Mining Inc. (OTC: FMNJ), Ambassadors International Inc. (Nasdaq: AMIE), Discovery Laboratories Inc. (Nasdaq: DSCO), Stem Cell Therapy International Inc. (OTCBB: SCII) and Speedus Corp. (Nasdaq: SPDE).

Visit http://www.otcpicks.com/microcap.htm today to join this growing community

BLACK DRAGON RESOURCE COMPANIES (OTC: BDGR)

"Up 225.00% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/BDGR.php

Black Dragon is an oil and gas exploration and production company currently focused on the acquisition of mature, producing and existing domestic oil and gas fields. This focus has eliminated exploration risk, reduced costs of completion, and provided rapid generation of income in a niche market where larger independent and major oil companies are not positioned to compete. Black Dragon intends to recomplete additional shallow producing wells and to expand its focus to include drilling of new wells, some to deeper levels, and to purchase additional leases.

BDGR News:

September 9 - Black Dragon Participation in Kingdom Energy Project

Black Dragon Resource Companies, Inc. (OTC: BDGR) ("the Company", "Dragon") has executed an agreement with Kingdom Energy Partners (KEP) for a 25% working interest (18.75% net revenue interest) in an oil development project in the Humble Field in Harris County, Texas. KEP is a privately held oil and gas company with a unique alliance with exclusive Patented and proprietary chemical technology called "Coriba™" related to Enhanced Oil Recovery (EOR).

The Humble Field was discovered in 1905 and has yielded more than 150 million barrels of oil. The oil was initially produced by Humble Oil Company, which subsequently became the anchor property for present day Exxon. The field is a major icon in the oil history of Texas, and Black Dragon is poised to join in that legacy.

This project is located in a low risk, proven salt dome reservoir with existing offset production. The lease covers 70 acres with 50 drillable acres. The program with KEP will involve drilling five wells to establish the EOR pattern. After initial production is established from these five wells, one will be converted to an injector for the introduction of Coriba. The project estimates initial production from 10-20 barrels per day per well under normal pumping conditions increasing to 25-80 BPD per well per day with EOR. With EOR this project could eventually result in the four production wells yielding between 100 and 300 BPD (3000 to 9000 BPM) to the 100% interest. Live Oak Operating will handle all drilling and daily operations.

According to Dr. Gerald Bailey, CEO of BDGR, EOR technology has the potential to be a major contributor in existing holdings for improving the recovery of thousands of barrels of previously by-passed oil in stripper fields of the type operated by Black Dragon.

Technical analysis by KEP estimates the Humble project could have recoverable reserves between 300,000 and 500,000 barrels of oil with the initial drilling and EOR program. Bill Hamm, President of KEP, said there is additional spacing in the lease covered by this agreement to replicate the initial four production wells with two more four well programs. BDGR will have first rights to participate in these next programs. This could bring total production to as much as 1000 BPD.

Dr. Bailey said that the first wells should be drilling by the end of October as the project is ready to start, and first production should occur before year end. Meanwhile Dragon will continue to explore the possibility of taking even a larger percentage in the project. Participation in Humble could be a potentially huge profit center for Dragon. Production for Dragon could be doubled. In addition there are several other acreage positions in the field that Dragon will have access to, including another 500 acres on the cap rock of the dome.

Black Dragon is an oil and gas exploration and production company currently focused on the acquisition of mature, producing and existing domestic oil and gas fields. This focus has eliminated exploration risk, reduced costs of completion, and provided rapid generation of income in a niche market where larger independent and major oil companies are not positioned to compete. Black Dragon intends to recomplete additional shallow producing wells and to expand its focus to include drilling of new wells some to deeper levels and to purchase additional leases.

FRANKLIN MINING INCORPORATED (OTC: FMNJ)

"Up 100.00% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/FMNJ.php

Franklin Mining, Inc. has mining and energy interests in the United States and Bolivia as well as energy interests in Argentina. Franklin Oil & Gas, Inc. and Franklin Mining, Bolivia are wholly owned subsidiaries. Franklin Mining, Inc. holds 51% ownership in both Franklin Oil & Gas, Bolivia S.A. and Franklin Oil & Gas International S.A. Visit www.FranklinMining.com for more information.

FMNJ News:

August 12 - Franklin Mining Announces Removal of Caveat Emptor by PinkSheets.com

Franklin Mining, Inc. (OTC: FMNJ) (Frankfurt: FMJ) Chairman William Petty announced that Issuer Services at Pink OTC Markets, Inc. has removed the caveat emptor warning previously assigned to the Company's listing at www.pinksheets.com.

The Company has published its 2008 Annual Report and First Quarter 2009 financial statements and released their accompanying Attorney's Letter with Respect to Current Information.

The Company's Information and Disclosure Statement was also published as of June 30, 2009 and is now available at www.pinksheets.com.

AMBASSADORS INTERNATIONAL INCORPORATED (NASDAQ: AMIE)

"Up 75.31% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/AMIE.php

Ambassadors International, Inc. is primarily a cruise company. The Company operates Windstar Cruises, an international, luxury cruise line. The Company is transitioning its headquarters from Newport Beach, California to Seattle, Washington. In this press release, any reference to "Company," "Ambassadors," "management," "we," "us" and "our" refers to Ambassadors International, Inc. and its management team.

AMIE News:

September 11 - Ambassadors International, Inc. Announces Restructuring Plan to Reduce Outstanding Debt by up to $70.5 Million

Ambassadors International, Inc. (Nasdaq: AMIE) announced a restructuring plan to reduce its outstanding debt by up to $70.5 million. The restructuring plan involves:

* A planned exchange offer for up to all of the Company's $97.0 million of outstanding 3.75% convertible senior notes due 2027 ("Convert Notes").

* Assuming 100% of the holders of the Convert Notes accept the offer and elect to exchange their Convert Notes, the proposed exchange consideration to be offered will be comprised of:

* $26.5 million aggregate principal amount of newly issued 10% senior secured notes due 2012 ("New Notes") on which interest will be paid in kind (or in cash at the Company's election); and

* Approximately 22.3 million shares of newly issued common stock, which will represent approximately 66.67% of the Company's outstanding common stock, immediately following the exchange offer.

* Holders of approximately 59.5% of the aggregate principal amount of the Convert Notes have entered into separate exchange offer commitment and support agreements with the Company pursuant to which the definitive terms of the exchange offer will be agreed and such holders have agreed to exchange their Convert Notes for the newly issued New Notes and shares of common stock in the exchange offer.

The planned exchange offer, if launched, will be subject to stockholder approval pursuant to the rules of The NASDAQ Global Market, as well as customary closing conditions. The Company will not receive any cash proceeds in connection with the exchange offer.

The Company anticipates that the restructuring plan will be completed during the fourth quarter of 2009.

Upon the commencement of the planned exchange offer, the Company will make available a Schedule TO, which will include an Offer to Exchange and related materials. These documents will set forth the complete terms and conditions of the exchange offer, and holders of the Convert Notes are urged to read these documents when they become available as they will contain important information. These and other related documents will be filed with the Securities and Exchange Commission and may be obtained at the Securities and Exchange Commission's website, www.sec.gov. These materials may also be obtained free of charge from the Company.

DISCOVERY LABS INCORPORATED (NASDAQ: DSCO)

"Up 79.12% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DSCO.php

Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 Surfactant Technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary Capillary Aerosolization Technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs is focused initially on developing its KL4 surfactant pipeline to build a pediatric franchise that will potentially address several respiratory conditions affecting neonates and young children, beginning with Respiratory Distress Syndrome (RDS).

DSCO News:

September 10 - Discovery Labs and FDA to Meet On September 29, 2009 to Discuss Potential Path for SURFAXIN Approval

Discovery Laboratories, Inc. (Nasdaq: DSCO) has received written notification from the U.S. Food and Drug Administration (FDA) that a meeting has been scheduled for September 29, 2009. This meeting will serve as a follow-up to the June 2 meeting with the FDA and the FDA's April 17 Complete Response letter. The objective of this meeting is to define the options available to Discovery Labs to resolve the remaining primary issue that Discovery Labs must address to gain U.S. marketing approval of Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.

At the upcoming September 29 meeting, Discovery Labs plans to discuss with the FDA a limited Surfaxin clinical trial design and whether conducting such trial, while simultaneously employing the fetal rabbit Biological Activity Test (BAT, a quality control and stability release test), could potentially address the key remaining requirement for Surfaxin approval. This approach was suggested by the FDA at the June 2 meeting as a way for Discovery Labs to increase the likelihood of gaining Surfaxin approval. In addition, Discovery Labs plans to review its ongoing quality improvement efforts, intended to further refine the BAT in accordance with Discovery Labs' continuing quality improvement initiatives, with the FDA.

Background

The April 17 Complete Response letter from the FDA and the June 2 meeting focused primarily on certain aspects of the BAT, specifically whether preclinical data generated using both the BAT and a well-established preterm lamb model of RDS adequately supports the comparability of Surfaxin clinical drug product to the to-be-manufactured Surfaxin, and whether the BAT can adequately distinguish change in Surfaxin biological activity over time.

During the conduct of Phase 3 clinical trials for Surfaxin, Discovery Labs employed an array of quality control tests, but did not employ the BAT to evaluate biological activity of the Surfaxin clinical drug product. After completing the Phase 3 clinical trials, in accordance with discussions with the FDA, Discovery Labs validated and implemented the BAT as a recurring quality control test to confirm biological activity for Surfaxin release and stability testing. Based on agreements reached in meetings with the FDA in 2006 and 2008, Discovery Labs conducted a series of preclinical experiments to establish comparability between Surfaxin drug product used in Phase 3 clinical trials and the Surfaxin drug product intended to be manufactured for commercial use. Accordingly, Discovery Labs initiated a series of side-by-side studies employing both the preterm lamb model of RDS and the BAT and believes that the correlated results demonstrate comparability and support approval of Surfaxin.

At the June 2 meeting with the FDA, Discovery Labs presented data from the preterm lamb model and BAT studies, together with a comprehensive statistical evaluation of such data, intended to establish the comparability of clinical drug product to Surfaxin drug product to be manufactured for commercial use. The comprehensive statistical evaluation was a comparative regression analysis using an accepted FDA statistical method. Discovery Labs believes that the data and related statistical evaluation are highly supportive of the comparability of clinical drug product to commercial Surfaxin.

However, the FDA stated at the June 2 meeting, that data generated from the preterm lamb model and BAT studies must demonstrate, in a point-to-point analysis, the same relative changes in respiratory compliance between both models over time. Based on this standard, Discovery Labs believes that establishment of comparability in this manner would be an extremely high hurdle and that, from the FDA's perspective, the data analysis provided by Discovery Labs did not meet that standard.

In addition, the FDA suggested that the comparability studies in the preterm lamb model and the BAT would not be necessary if the BAT had been implemented to assess Surfaxin drug product used in the Phase 3 clinical trials. The FDA also suggested that, to increase the likelihood of gaining Surfaxin approval and as an alternative to demonstrating comparability using the preterm lamb model and BAT, Discovery Labs could consider conducting a limited clinical trial, while simultaneously employing the BAT, as a path forward to Surfaxin approval.

STEM CELL THERAPY INTERNATIONAL (OTCBB: SCII)

"Up 69.81% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/SCII.php

Stem Cell Therapy International, Inc., through its wholly owned subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell technology and the sale of stem cell products, as well as the provision of information, education, and referral services. It provides allo stem cell biological solutions that are used in the treatment of patients suffering from degenerative disorders of the human body, such as Alzheimer's Disease, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, and diabetes, as well as certain types of cancer. The company's stem cell biological solutions can be used to alleviate the side effects of chemotherapy. Its principal stem cell products are solutions containing allo stem cell biological solutions, either adult stem cells, and stem cells that are extracted from umbilical cord blood. It intends to offer biological solutions containing stem cell products primarily in the United States to universities, institutes, and privately funded laboratory facilities for research purposes and clinical trials. The company was incorporated in 2004 and is headquartered in Tampa, Florida.

SCII News:

September 10 - Stem Cell Therapy International Inc. Announces Histostem Litigation Settlement

Stem Cell Therapy International Has Agreed to Be a Party to the Settlement; Settlement Requires Histostem and Stem Cell Therapy International Inc. to Merge

Stem Cell Therapy International Inc. (OTCBB: SCII) announced that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation ("Histostem USA") and Histostem Corporation, a Korean Corporation ("Histostem Korea"). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent that at the close of the merger, SCII will acquire no less than 90% of the total fully diluted equity of Histostem Korea.

For the consideration provided by Histostem USA, including but not limited to a waiver of claims and a general release, Histostem Korea and SCII have agreed to pay Histostem USA $100,000 in cash, which will be divided into three equal payments over a two year period; and seven and one half percent (7.50%) of the fully diluted total outstanding shares of SCII common stock following the close of the merger between Histostem Korea and SCII. The management of Stem Cell Therapy International, Inc. will continue to finalize a new merger agreement between SCII and Histostem Korea in the next fifteen days.

Andrew J. Norstrud, Chief Financial Officer, states, "Over the past year, it has been very challenging to make significant progress in operations, obtain the necessary financing to execute our global strategy and complete the merger while we were waiting for the final resolution in the Histostem Korea litigation." Mr. Norstrud also stated, "We appreciate all of the investors that have continued to support SCII and we look forward to completing this merger and obtaining the necessary financing to enable us to accelerate our strategic initiatives in the near future."

The Company plans to leverage Histostem Korea's technology to be the state-of-the-art conduit for bringing Asian adult stem cells into the U.S. for clinical trials and the treatment of conditions on which Americans spend billions of dollars annually. This is predicated on successful clinical trial results by Histostem Korea for Male Pattern Baldness, Buerger's Disease and other conditions, whose repository of over 80,000 cord blood units has consistently met the rigorous standards of the Korean FDA. This has made Histostem Korea the largest repository of cord blood in the world, and one of the first to actually profit from sales of its own stem cell-derived products.

ABOUT AMSTEM INTERNATIONAL, INC.

AmStem International, Inc. is a wholly owned subsidiary of SCII, and a new biotechnology company based in Northern California, in the watershed of stem cell innovation fueled by President Obama's recent announcement to lift Federal funding limitations for stem cell research. AmStem provides biotherapeutic and cosmetic stem cell products, stem cell collection and storage know-how, and access to nanotechnology vital to cutting edge stem cell research. Further information about AmStem International, Inc. can be found by contacting David Stark, SCII President, at the email posted below.

ABOUT HISTOSTEM CORPORATION, LTD.

Histostem Corp., Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has 56 full-time employees and 28 part-time employees. Histostem's intellectual property portfolio consists of five patents that have been granted and six patents pending. To its knowledge Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. Further information about Histostem Corporation, Ltd. can be found by contacting David Stark, SCII President, at the email posted below.

SPEEDUS CORPORATION (NASDAQ: SPDE)

"Up 24.40% on Friday"

Detailed Quote: http://www.otcpicks.com/quotes/SPDE.php

Speedus Corp., through its subsidiaries, engages in healthcare, restaurant, and wireless businesses in the United States. The company has co-invested with Siemens Corporate Research, Inc., a subsidiary of Siemens Corporation, in Zargis Medical Corp. to develop advanced diagnostic decision support products and services that automatically analyze acoustical data from a patient to determine physiologically significant features useful in medical diagnosis for primary care physicians, pediatricians, cardiologists, and other healthcare professionals. It owns 90% of F&B Gudtfood, the creator and operator of the original Eurocentric cafe, which operates a store in Manhattan. The company has a portfolio of patents that provide high-speed wireless communication systems. In addition, it offers Local Multipoint Distribution Service (LMDS) license for developing and deploying LMDS technology that is used for various fixed wireless purposes, including wireless local loop telephony, high-speed Internet access, and two-way teleconferencing. The company, formerly known as SPEEDUS.COM, Inc., was founded in 1995 and is based in New York, New York.

SPDE News:

September 11 - Density Dynamics Develops Distribution; Signs International Rep Agreement

Density Dynamics, a majority owned subsidiary of Speedus Corp. (Nasdaq: SPDE), announced that it has signed an International Representation agreement covering India with Graphay, Inc.

"We are excited to establish a sales and distribution channel for the cutting-edge DRAM-based SSD's built for high speed data enterprise users. My experience at Wachovia in the data center environment led me to witness the Jet.io SSD. Its power and performance capabilities are highly anticipated in the Indian market and together with Graphay's technologies, will address pressing needs of our Enterprise customers. We look forward to a long and fruitful relationship," said Ashish Majmundar, CEO and founder of Graphay.

ABOUT DENSITY DYNAMICS

Density Dynamics, a majority owned subsidiary of Speedus Corp., is a pioneer in the solid-state storage and I/O acceleration technology. Its high performance RamFlash solid-state storage and computing devices are designed to reduce I/O bottlenecks while also reducing power, cooling, and rack space requirements.

ABOUT GRAPHAY

Graphay, headquartered in Matthews, NC, is an Enterprise IT Solutions Provider to customers in India & Israel. Graphay offers end-to-end architecture design, desktop and data center virtualization, along with best-in-breed products from its Global technology partners.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.

Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.

Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.